Dr Matthew Goetz reviews what differentiates abemaciclib, the latest CDK4/6 inhibitor FDA-approved for HR+ metastatic breast cancer, from ribociclib and palbociclib.
Related Items
TOP - February 2019, Vol 12, No 1 published on January 29, 2019 in Breast Cancer
Web Exclusives published on January 28, 2019 in Breast Cancer
Web Exclusives published on October 22, 2018 in Breast Cancer
Web Exclusives published on October 15, 2018 in Breast Cancer
Last modified: December 8, 2017